Stockreport

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]

Armata Pharmaceuticals, Inc.  (ARMP) 
PDF First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES Jan. 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (" [Read more]